Fundamental Analysis of SURFACE ONCOLOGY INC(NASDAQ:SURF) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to SURF. SURF was compared to 588 industry peers in the Biotechnology industry. SURF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SURF is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SURF has reported negative net income.

SURF had a negative operating cash flow in the past year.

SURF had negative earnings in 4 of the past 5 years.

SURF had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The profitability ratios for SURF are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SURF so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SURF does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for SURF has been increased compared to 1 year ago.

SURF has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, SURF has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -6.54, we must say that SURF is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -6.54, SURF is not doing good in the industry: 72.65% of the companies in the same industry are doing better.

There is no outstanding debt for SURF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.54

ROIC/WACCN/A

WACC9.86%

2.3 Liquidity

SURF has a Current Ratio of 3.60. This indicates that SURF is financially healthy and has no problem in meeting its short term obligations.

SURF's Current ratio of 3.60 is on the low side compared to the rest of the industry. SURF is outperformed by 64.62% of its industry peers.

A Quick Ratio of 3.60 indicates that SURF has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.60, SURF is doing worse than 64.10% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.6
Quick Ratio	3.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SURF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.60%.

Looking at the last year, SURF shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

Measured over the past years, SURF shows a quite strong growth in Revenue. The Revenue has been growing by 18.57% on average per year.

EPS 1Y (TTM)-18.6%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q0%

Revenue 1Y (TTM)-100%

Revenue growth 3Y24.89%

Revenue growth 5Y18.57%

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 5.56% on average over the next years.

Based on estimates for the next years, SURF will show a very strong growth in Revenue. The Revenue will grow by 21.55% on average per year.

EPS Next Y-41.08%

EPS Next 2Y-21.95%

EPS Next 3Y6.29%

EPS Next 5Y5.56%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-37.88%

Revenue Next 5Y21.55%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SURF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SURF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-21.95%

EPS Next 3Y6.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SURF!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SURFACE ONCOLOGY INC

NASDAQ:SURF (9/7/2023, 7:23:11 PM)

After market: 1.07 0 (0%)

1.07

-0.01 (-0.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap65.08M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.6
Quick Ratio	3.6
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-18.6%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-41.08%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3Y24.89%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SURFACE ONCOLOGY INC (SURF)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens